Abstract 73P
Background
The number of typical and atypical (defined as mitoses with any morphological appearance other than the typical forms) mitotic figures (MFs) and a high atypical-to-typical mitosis ratio are strongly associated with tumour aggressivity, survival rates, and a predictor of poor response to chemotherapy in breast cancer. Manual detection is time consuming, especially on whole slide images (WSIs). An automated approach is therefore necessary to investigate these aspects on a larger scale. We demonstrate that deep learning can be used to automate this detection, improving on the performance of pathologists.
Methods
All MFs in the mammary carcinoma dataset (21 hematoxylin and eosin (H&E)-stained WSIs with ∼14 000 MFs and ∼36 000 hard negatives) were labelled as typical or atypical. These slides (originally scanned on a Leica scanner) were then rescanned on six other scanners (2x Hammamatsu, 2x 3DHISTECH, Philips, Olympus), and the annotations were registered. This gave a large, multi-scanner dataset, which was used to train a YOLOv6 deep learning object detection model. For testing, all MFs in the (human) TUPAC16 and MIDOG21 datasets were labelled by two pathologists as either typical or atypical. In cases of disagreement, a third reader gave a consensus. We used the alternative version of the TUPAC16 dataset provided by the same authors as the MIDOG21 dataset to reduce potential label bias. We then ran our model on these images and compared the mean average precision (mAP) vs the consensus to the mAPs of the two individual pathologists vs the consensus.
Results
The mAP of our model (0.80) was higher than the average mAP of the two pathologists (0.75, p<0.05), showing that the model can successfully automate the process of MF detection. There was considerable disagreement in the labelling by the two pathologists (14% of cases). By automating the process we reduce this variability, meaning we can more consistently predict clinical outcomes (e.g. survival rates) from our results.
Conclusions
The numbers of both typical and atypical MFs are indicators of patient survival and response to treatment. We have demonstrated an automated deep learning model that can accurately detect these figures and could thus be used for patient survival prediction.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Tribun.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
24P - Fibroblast growth factor receptor (FGFR) as a target for epigenetic therapies: A case review for a new approach to target tumors with somatic mutations/amplifications of FGFR
Presenter: M. Nezami
Session: Cocktail & Poster Display session
Resources:
Abstract
25P - Relationship between aberrant methylation of CpG islands of microRNA gene promoters and changes in their expression in epithelial ovarian cancer
Presenter: Irina Pronina
Session: Cocktail & Poster Display session
Resources:
Abstract
26P - 3MST: A potential workhorse in H2S signaling trimmed by microRNA-548 in breast cancer
Presenter: Alyaa Dawoud
Session: Cocktail & Poster Display session
Resources:
Abstract
29P - A phase I, open-label, dose escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics/pharmacodynamics, antitumor activity of QL1604, a humanized anti-PD-1 mAb, in patients with advanced solid tumors
Presenter: Yun Fan
Session: Cocktail & Poster Display session
Resources:
Abstract
30P - Deep learning approach for discovering new predictive histological features of immunotherapy response
Presenter: Saima Ben Hadj
Session: Cocktail & Poster Display session
Resources:
Abstract
32P - Clinical efficacy and safety of an immune checkpoint inhibitor in combination with regorafenib therapy as second-line regimen for patients with unresectable hepatocellular carcinoma
Presenter: Jinpeng Li
Session: Cocktail & Poster Display session
Resources:
Abstract
33P - Nomogram to predict survival of patients with unresectable melanoma receiving immune checkpoint inhibitors
Presenter: Eftychia Chatziioannou
Session: Cocktail & Poster Display session
Resources:
Abstract
34P - Targeting LSD1 rescues MHC-I antigen presentation and overcomes resistance to PD-L1 checkpoint blockade in small cell lung cancer
Presenter: Evelyn Nguyen
Session: Cocktail & Poster Display session
Resources:
Abstract
36P - Therapeutic vaccination with HPV-16 oncoproteins fused into a checkpoint modifier of early T cell activation protects against HPV-associated tumors in a preclinical model
Presenter: Susan Currie
Session: Cocktail & Poster Display session
Resources:
Abstract
37P - Dose transition pathways for time-to-event continual reassessment method (TITE-CRM): Will imposing a waiting time result in better performance?
Presenter: Zhulin Yin
Session: Cocktail & Poster Display session
Resources:
Abstract